Safety warning: DAAs linked to hepatitis B risk

The hep C medicines have been associated with reactivation of the hep B virus, which can lead to liver failure and even death A TGA review has found evidence of an association between treatment of chronic HCV with DAA medicines and reactivation of HBV in a small number of patients with current or previous HBV